CYTK ▲ +0.6% - Cytokinetics, Incorporated $CYTK - Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine Cytokinetics shares rose 0.6% following the announcement of positive results from the ACACIA-HCM trial, which were presented at the European Society of Cardiology Congress 2026 and published in The New England Journal of Medicine. The positive clinical trial data and high-profile publication in a top-tier medical journal likely supported investor confidence in the company's heart condition treatment candidate. 28-AUG-2026 05:45 AM ET